Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...

Should we use AI to pre-screen whether people can see a human therapist? And should we use AI to do initial intervention?

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Checkout speed has become one of the most critical factors in today's retail experience. Tolerance for waiting time at the ...

Q4 2025 Earnings Call Transcript January 16, 2026 State Street Corporation beats earnings expectations. Reported EPS is $2.97 ...

Some citizens of the United States seeking to move and work in Canada have advantages and facilitations to help them do so ...

By Dr Bertrand Ramcharan Honorary Commissioner of the International Commission of Jurists There are many aspects of the history of independent Guyana that ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Hello New York! I want to thank the Pride of The Orange marching band. The best marching band in the country as far as I’m ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany? 12 January, 2026 ? Boehringer Ingelheim today announced a strategic ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

AI firm promises HIPAA-compliant integrations as chatbot moves into hospital admin Fresh from watching rival OpenAI stick its ...